Malignant Solid Tumour Clinical Trial
Official title:
A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours
There is a great need for new therapies for carcinomas that have progressed on or not
responded to current therapy. There are no approved Met targeted agents in standard clinical
use. In the population of subjects with advanced carcinomas that are unresponsive to
standard of care, and based on the relatively safe, reversible and monitorable toxicity
profile of ASLAN002 in non clinical studies, the potential for benefit from ASLAN002
outweighs the potential risks for toxicity.
The purpose of this study is to identify the maximum tolerated dose of ASLAN002 in subjects
with advanced or metastatic solid tumours, as well as to define the overall safety profile
of ASLAN002.
The purpose of the study is
- To identify the maximum tolerated dose (MTD) of ASLAN002 in subjects with advanced or
metastatic solid tumours
- To define the overall safety profile of ASLAN002
- To assess the effects of ASLAN002 on overall cardiac function as measured by blood
pressure (BP), heart rate (HR), electrocardiogram (ECG) changes, and left ventricular
function
Secondary:
- To characterize the pharmacokinetics (PK) of ASLAN002 and its N-oxide metabolite,
following single and multiple dosing
- To provide a preliminary assessment of anti-tumour activity, as assessed by the Overall
Response Rate (ORR) and changes from baseline in tumour size
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00551096 -
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01023737 -
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01435096 -
BN80927 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01951846 -
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
|
Phase 1 | |
| Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01554371 -
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01309490 -
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01286896 -
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01376505 -
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00388427 -
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01611857 -
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
|
Phase 1/Phase 2 | |
| Completed |
NCT02843204 -
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02853903 -
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
|
Phase 2 | |
| Completed |
NCT01618136 -
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00801151 -
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02786628 -
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT01184807 -
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00969410 -
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
|
Phase 1 | |
| Completed |
NCT02857920 -
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
|
Phase 1/Phase 2 |